It's anticipated that they will be announced before month's end....

It's anticipated that they will be announced before month's end. Afandin's exclusivity agreement expires around the end of the month with regards to ATL1101 so we will hear something about this, the announcement in February with regards to TJAB and ATL1102 mentioned that they expect to reach agreement before 30 June however both parties were hopeful to do it sooner, and ATL1103 has been mentioned that they are in discussion with regards to phase II trials and expect to be in a position to announce an update by end June.

Where ATL1103 is concerned, if they do reach an agreement, I imagine it will be similar to ISIS/Biogen deal at the beginning of the year as they were in the development stage and that involved a $29m upfront and ISIS had an option to commercialise on successful p2/3 trials. So if a deal isn't done, I would expect that it is because the pharma wasn't prepared to make a similar deal. With the other two though, I'm not sure as to what the deal could potentially be, PeaceAKKI has previously indicated though that they would expect it to only be a mill or two.